Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Patients who will be scheduled for intravitreal injection of Ranibizumab or Bevacizumab will
be recruited in this prospective self-controlled trial. Fundus photography will carried out
at baseline immediately before injection and at 3, 7 days and 30 days after the first
injection. Using image analysis software, measurements summarized as the central retinal
artery equivalent (CRAE) and central retinal vein equivalent (CRVE).
Null Hypothesis: There is no significant difference between arteriolar/venular diameter
before and after injection of intravitreal ranibizumab/bevacizumab in the treated and
untreated eye